Allergan’s Stock Price Performance in September




Allergan (AGN) is a specialty pharmaceutical company that develops a variety of products through internal programs as well as in collaboration with other companies. Allergan’s stock price has decreased by nearly 0.6% to its closing price of $191.31 on September 21, compared to its closing price on September 20.

The chart below compares the changes in analysts’ recommendations since January. This series covers some of Allergan’s developments in September.

Article continues below advertisement

Stock price performance

Allergan’s stock price has increased ~16.9% YTD (year-to-date) through September 21. However, it has posted a 12-month return of -5.6%. Allergan’s stock price has decreased 0.2% during the month through September 21.

Analysts’ recommendations

On September 21, 23 analysts tracked Allergan stock. Four analysts recommended a “strong buy,” 12 analysts recommended a “buy,” and seven analysts recommended a “hold.” None of the analysts recommended a “sell” for Allergan stock. The consensus rating for Allergan stands at 2.13, which represents a “strong buy” for long-term growth investors as well as value investors. 

Analysts expect to see 10.6% growth in Allergan stock over the next 12 months to a target price of $211.58 per share, compared to its closing price of $191.31 per share on September 21.

The iShares US Pharmaceuticals ETF (IHE) holds 5.7% of its total investments in Allergan (AGN), 6.9% in Eli Lilly & Co. (LLY), 8.2% in Merck & Co. (MRK), and 10.7% in Johnson & Johnson (JNJ).


More From Market Realist